Mnemosyne Pharmaceuticals Garners $5,400,000 Series A Financing

  • Feed Type
  • Date
    2/17/2012
  • Company Name
    Mnemosyne Pharmaceuticals
  • Mailing Address
    3 Davol Square Providence, RI 02903
  • Company Description
    The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
  • Website
    http://www.mnemosynepharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,400,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company said that it will use the new funds in support of its drug discovery programs, including the identification of lead product candidates for treatment of schizophrenia and other neuropsychiatric disorders.
  • M&A Terms
  • Venture Investor
    Access BridgeGap Ventures
  • Venture Investor
    Slater Technology Fund

By posting a comment, you agree to our terms and conditions.